The Greenrose Holding Company Inc. (GNRS)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
The Greenrose Holding Company Inc. (GNRS) trades at $0.00 with AI Score 43/100 (Grade C). The Greenrose Holding Company Inc. (GNRS) operates in the medical cannabis sector, focusing on cultivation, processing, and distribution through its subsidiaries. Market cap: $1,768, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for GNRS: GNRS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates GNRS against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
GNRS: the 1 perspectives are evenly split.
How is this calculated? →The Greenrose Holding Company Inc. (GNRS) Healthcare & Pipeline Overview
The Greenrose Holding Company Inc., established in 2014, specializes in the cultivation, processing, and distribution of medical cannabis products through its subsidiaries. Headquartered in Amityville, New York, the company operates within the evolving healthcare sector, navigating regulatory complexities inherent to the cannabis industry while serving a growing market for specialized therapeutic applications.
What Is the Investment Thesis for GNRS?
The Greenrose Holding Company Inc. operates within the expanding cannabis industry, specifically targeting the medical cannabis segment, which presents a significant growth catalyst. Despite a reported market capitalization of 2K and a P/E ratio of 0.0, the company exhibits strong financial metrics with a profit margin of 70.6% and a gross margin of 59.1%, suggesting operational efficiency in its core activities. These margins indicate a potentially profitable business model, although the zero market cap and P/E suggest either nascent profitability or significant financial restructuring. A key value driver is its participation in a growing market for medical cannabis, driven by increasing legalization and patient adoption. However, the company faces substantial risks, including the regulatory uncertainties inherent in the cannabis sector and intense competitive pressures. Its extremely high negative Beta of -170.34 indicates an unusual and highly volatile inverse correlation to the broader market, suggesting significant idiosyncratic risk or data anomaly. Investors should critically assess the company's ability to achieve sustainable profitability and navigate the complex, evolving legal landscape for cannabis, particularly given its OTC listing and unknown disclosure status.
Based on FMP financials and quantitative analysis
GNRS Key Highlights
- Market Capitalization reported at $0.00 billion, indicating a very small or distressed valuation.
- P/E Ratio of 0.0, suggesting either negative earnings or that the company is not yet profitable on a per-share basis.
- Profit Margin of 70.6%, demonstrating high profitability from its operations relative to revenue.
- Gross Margin of 59.1%, indicating strong efficiency in converting raw materials into products before operating expenses.
- Beta of -170.34, an exceptionally high negative value suggesting extreme inverse correlation to market movements, which could imply significant volatility or data anomaly.
Who Are GNRS's Competitors?
GNRS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
| EGRX Eagle Pharmaceuticals, Inc. | $0.67 | +0.00% | $8.82M | 60 |
| ADMP Adamis Pharmaceuticals Corporation | $0.78 | +0.85% | $7.25M | 61 |
| SGIOY Shionogi & Co., Ltd. | $8.97 | +3.70% | $15.27B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GNRS's Key Strengths?
- High profit margin of 70.6% and gross margin of 59.1% indicate strong operational efficiency.
- Participation in the growing medical cannabis market, driven by increasing legalization and acceptance.
- Established operations in cultivation, processing, and distribution of cannabis products.
- Headquartered in Amityville, US, with a defined operational base.
What Are GNRS's Weaknesses?
- Market capitalization of 2K and P/E ratio of 0.0 suggest significant financial challenges or nascent profitability.
- OTC listing on the 'OTC Other' tier implies increased scrutiny and potential liquidity issues.
- Unknown disclosure status, leading to limited transparency for investors.
- Extremely high negative Beta (-170.34) indicates unusual volatility or data anomaly, potentially signaling high risk.
What Could Drive GNRS Stock Higher?
- Potential for new state-level medical cannabis legalizations could open up new markets and revenue streams for Greenrose, expanding its operational footprint and patient access.
- Continued growth in the overall medical cannabis market, driven by increasing patient adoption and physician recommendations, could boost demand for the company's products.
- Any strategic partnerships or acquisitions within the fragmented cannabis industry could enhance Greenrose's market position and operational scale, subject to regulatory approvals.
- Successful product diversification into new derivative forms (e.g., edibles, concentrates) could capture additional market share and increase average revenue per patient.
- Improvements in operational efficiency and supply chain management could lead to enhanced profitability, particularly given the company's high gross and profit margins.
What Are the Key Risks for GNRS?
- Financial-distress signal — its Altman Z-Score of -1.28 sits in the distress zone (elevated bankruptcy risk).
- Persistent regulatory uncertainty and the risk of adverse legislative changes at federal or state levels could significantly impact the company's operations and market access.
- Intense competition within the cannabis industry from larger, better-capitalized multi-state operators could pressure Greenrose's market share and pricing power.
- The 'Unknown' disclosure status and 'OTC Other' listing present significant transparency and liquidity risks, making it difficult for investors to assess and trade the stock.
- The reported 2K market capitalization and 0.00 P/E ratio, despite high margins, suggest underlying financial distress or a highly speculative valuation, posing a risk to investor capital.
- The extremely high negative Beta of -170.34 indicates extreme volatility and an unusual market correlation, which could lead to unpredictable and significant share price movements.
What Are the Growth Opportunities for GNRS?
- **Expansion into New State-Legal Medical Cannabis Markets**: The ongoing trend of state-level medical cannabis legalization across the United States presents a significant growth avenue for Greenrose. As more states establish regulated medical cannabis programs, the company can strategically expand its cultivation, processing, and distribution networks into these new territories. This expansion would involve securing necessary licenses, establishing local supply chains, and building patient bases. The potential market size for medical cannabis continues to grow, with new states adding millions of potential patients, offering substantial revenue growth opportunities over the next 3-5 years as these markets mature and regulatory frameworks stabilize.
- **Product Diversification and Innovation**: Beyond traditional medical cannabis flower, there is a growing demand for a wider range of derivative products such as edibles, tinctures, concentrates, and topicals. Greenrose can capitalize on this trend by investing in research and development to expand its product portfolio. Introducing innovative product forms and delivery methods can appeal to a broader patient demographic and address specific therapeutic needs, enhancing market penetration and brand loyalty. This strategy could unlock new revenue streams and strengthen the company's competitive position within the next 2-4 years, tapping into a market segment seeking convenience and precise dosing.
- **Enhancing Vertical Integration and Supply Chain Optimization**: Strengthening vertical integration, from seed-to-sale, offers Greenrose greater control over product quality, cost efficiencies, and supply chain resilience. By optimizing its cultivation, processing, and distribution operations, the company can reduce reliance on third-party suppliers, mitigate supply chain risks, and improve profit margins. Investments in advanced cultivation technologies, efficient processing equipment, and robust distribution logistics can lead to significant operational improvements. This focus on internal capabilities can drive sustained growth and cost leadership over the long term, typically yielding benefits within a 3-6 year timeframe as systems are fully implemented and optimized.
- **Strategic Partnerships and Acquisitions**: The fragmented nature of the cannabis industry presents opportunities for consolidation. Greenrose could pursue strategic partnerships with other licensed operators or acquire smaller, complementary businesses to expand its geographic reach, enhance its product offerings, or gain access to new intellectual property. Such inorganic growth strategies can accelerate market entry into new regions, consolidate market share, and leverage synergies in operations and distribution. These opportunities are ongoing, with potential for significant impact within 1-3 years depending on market conditions and available capital, allowing the company to scale operations more rapidly.
- **Targeted Research and Development for Specific Medical Conditions**: As understanding of cannabis's therapeutic potential grows, there is an increasing opportunity to develop specialized cannabis products tailored to specific medical conditions or patient populations. Greenrose could invest in R&D to identify and cultivate specific cannabinoid profiles or develop formulations aimed at conditions like chronic pain, epilepsy, or anxiety. This specialization could create premium product lines and establish the company as a leader in particular therapeutic niches. This long-term growth driver, with a timeline of 4-7 years, could differentiate Greenrose significantly in the medical cannabis market, supported by clinical evidence and physician recommendations.
What Opportunities Does GNRS Have?
- Expansion into newly legalized medical cannabis markets across various states.
- Diversification of product offerings to include a wider range of derivative cannabis products.
- Strategic partnerships or acquisitions to consolidate market share and expand geographic reach.
- Advancements in cannabis research leading to new therapeutic applications and product development.
What Threats Does GNRS Face?
- Ongoing regulatory uncertainties and changes in the legal landscape for cannabis at both state and federal levels.
- Intense competitive pressures from established multi-state operators and new market entrants.
- Potential for federal prohibition or restrictive policies impacting the entire cannabis industry.
- Challenges in accessing traditional banking and financial services due to federal illegality of cannabis.
What Are GNRS's Competitive Advantages?
- Regulatory compliance and licensing in specific jurisdictions, which can be a significant barrier to entry.
- Established cultivation and processing infrastructure, representing substantial capital investment.
- Proprietary strains or cultivation techniques that yield specific cannabinoid profiles for medical use.
- Brand recognition and patient trust built through consistent product quality and efficacy in the medical market.
What Does GNRS Do?
Established in 2014 and headquartered in Amityville, New York, The Greenrose Holding Company Inc. operates through its subsidiaries to manufacture and distribute cannabis products. The company's core business revolves around the cultivation, processing, and packaging of medical cannabis and related derivative items, positioning it within the specialized healthcare segment of drug manufacturers. Since its inception, Greenrose has focused on building an operational footprint that supports the entire lifecycle of cannabis production, from initial cultivation in controlled environments to advanced processing techniques that yield various medical cannabis products. This integrated approach allows the company to maintain quality control and ensure compliance with the stringent regulations governing the medical cannabis industry. Its product portfolio likely encompasses a range of medical cannabis formats, catering to diverse patient needs and prescription requirements within legal jurisdictions. Operating in the rapidly evolving cannabis industry, Greenrose aims to leverage its operational capabilities to capture market share in a sector characterized by ongoing legislative changes and increasing consumer acceptance. The company's strategic focus on medical applications underscores its commitment to the healthcare sector, differentiating its offerings from broader recreational markets. Its presence in Amityville, US, serves as a hub for its operations, supporting its mission to deliver specialized cannabis products to patients.
What Products and Services Does GNRS Offer?
- Cultivate medical cannabis plants in controlled environments to ensure quality and consistency.
- Process harvested cannabis into various forms, including flower, oils, and other derivative products.
- Package medical cannabis products for distribution, adhering to strict regulatory requirements.
- Distribute medical cannabis and related items to licensed dispensaries or directly to patients in authorized markets.
- Operate through subsidiaries, indicating a structured approach to managing diverse operations.
- Focus on the medical cannabis sector, distinguishing its operations from recreational markets.
How Does GNRS Make Money?
- Generate revenue through the sale of cultivated medical cannabis flower to licensed dispensaries or directly to patients.
- Derive income from the sale of processed cannabis products, such as oils, edibles, and tinctures, to the medical market.
- Operate a vertically integrated model, controlling aspects from cultivation to distribution, to optimize costs and quality.
- Adhere to state-specific regulatory frameworks for cannabis production and sales, ensuring compliance for market access.
What Industry Does GNRS Operate In?
The Greenrose Holding Company Inc. operates within the dynamic and rapidly evolving cannabis industry, specifically positioned in the Drug Manufacturers - Specialty & Generic segment of the Healthcare sector. This industry is characterized by significant regulatory flux, with ongoing state-level legalization efforts for both medical and recreational cannabis contributing to market expansion. The global medical cannabis market is projected to continue its robust growth, driven by increasing acceptance of cannabis for therapeutic purposes and advancements in research. Greenrose's focus on cultivation, processing, and distribution of medical cannabis places it in a competitive landscape alongside numerous multi-state operators (MSOs) and smaller, localized players. The company must navigate a complex patchwork of state and federal laws, which often creates barriers to interstate commerce and capital access. Its operational model aims to capitalize on the growing demand for specialized cannabis products, competing on factors such as product quality, brand reputation, and compliance adherence within its operational jurisdictions.
Who Are GNRS's Key Customers?
- Licensed medical cannabis dispensaries that serve registered patients.
- Registered medical cannabis patients, where direct-to-patient sales are permitted.
- Healthcare providers or clinics that recommend or prescribe medical cannabis.
- Wholesale buyers in regulated medical cannabis markets.
Company Profile
The Greenrose Holding Company Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Amityville, US. The company is led by CEO Nicole Conboy. GNRS has traded publicly since 2020.
F-Score 6/9Financial Health
The Greenrose Holding Company Inc.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -1.28 places it in the distress zone, a signal of elevated financial risk.
ROE 15%Key Financial Metrics
Return on equity for The Greenrose Holding Company Inc. stands at 14.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 7.5%, showing how much profit it generates from its asset base. GNRS trades at a trailing price-to-earnings ratio of 0.00, below the Healthcare sector average of ~23x. A current ratio of 0.21 means current liabilities exceed short-term assets, a liquidity point worth watching.
GNRS Valuation & Market Position
With a 2K market cap, The Greenrose Holding Company Inc. sits in the micro-cap segment of the market. Relative to its peer group, GNRS's quantitative score of 43/100 is below the peer average of 66/100.
GNRS Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- High profit margin of 70.6% and gross margin of 59.1% indicate strong operational efficiency.
- Participation in the growing medical cannabis market, driven by increasing legalization and acceptance.
- Established operations in cultivation, processing, and distribution of cannabis products.
- Headquartered in Amityville, US, with a defined operational base.
Bear Case
- Market capitalization of 2K and P/E ratio of 0.0 suggest significant financial challenges or nascent profitability.
- OTC listing on the 'OTC Other' tier implies increased scrutiny and potential liquidity issues.
- Unknown disclosure status, leading to limited transparency for investors.
- Extremely high negative Beta (-170.34) indicates unusual volatility or data anomaly, potentially signaling high risk.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
GNRS Latest News
No recent news available for GNRS.
GNRS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GNRS.
Price Targets
Wall Street price target analysis for GNRS.
GNRS MoonshotScore
What does this score mean?
The MoonshotScore rates GNRS's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Nicole Conboy
CEO
Nicole Conboy serves as the CEO of The Greenrose Holding Company Inc., overseeing its operations in the medical cannabis sector. While specific details regarding her prior career history and educational background are not provided, her role as CEO indicates significant leadership experience. In this capacity, she is responsible for managing the company's 91 employees and guiding its strategic direction within the complex and evolving cannabis industry. Her leadership would typically encompass operational oversight, financial management, and navigating the intricate regulatory environment inherent to the cultivation, processing, and distribution of medical cannabis products.
Track Record: Under Nicole Conboy's leadership, The Greenrose Holding Company Inc. has maintained its operational focus on the cultivation, processing, and packaging of medical cannabis products. Her tenure has involved managing the company's workforce of 91 employees and ensuring adherence to the stringent regulatory requirements of the cannabis industry. Key strategic decisions under her guidance would likely include efforts to optimize production efficiencies and maintain compliance, positioning the company within its niche in the healthcare sector. Specific achievements or milestones are not detailed in the provided information.
GNRS OTC Market Information
The 'OTC Other' tier, also known as the Pink Sheets or Pink Current, represents the lowest and most speculative tier of the OTC market. Unlike companies listed on major exchanges like NYSE or NASDAQ, or even higher OTC tiers like OTCQX or OTCQB, companies on 'OTC Other' have minimal or no disclosure requirements. This tier is often home to shell companies, distressed businesses, or those with limited public information. Investors face significantly higher risks due to the lack of transparency and regulatory oversight compared to more regulated markets, making comprehensive due diligence critically important.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Extreme lack of transparency due to 'Unknown' disclosure status, making fundamental analysis nearly impossible.
- Significantly higher fraud risk compared to regulated exchanges due to minimal oversight and reporting requirements.
- High volatility and potential for price manipulation due to low trading volume and limited market information.
- Difficulty in obtaining accurate and timely financial information, hindering informed investment decisions.
- Limited analyst coverage and institutional interest, leading to a less efficient market for the stock.
- Verify the company's operational existence and physical assets through independent means.
- Seek any available, albeit limited, public filings or press releases directly from the company or third-party sources.
- Research management's background and track record beyond what is publicly stated.
- Assess the actual market for its products/services and its competitive position, independent of company claims.
- Understand the specific state-level cannabis regulations it operates under and its compliance history.
- Evaluate the company's capital structure and any outstanding debt or liabilities, if discoverable.
- Consider the potential for reverse stock splits or other corporate actions that could dilute shareholder value.
- Clear and consistent communication channels (e.g., active website, verifiable contact information).
- Tangible evidence of operations, such as cultivation facilities or processing plants, that can be independently verified.
- Demonstrable product lines and distribution networks within legal cannabis markets.
- Any verifiable licenses or permits issued by state regulatory bodies for cannabis operations.
- A stable management team with a track record in the cannabis or related industries.
GNRS Healthcare Stock FAQ
What does The Greenrose Holding Company Inc. do?
The Greenrose Holding Company Inc. specializes in the cultivation, processing, and distribution of medical cannabis products through its various subsidiaries. Established in 2014 and headquartered in Amityville, New York, the company operates within the healthcare sector, specifically targeting the drug manufacturers - specialty & generic industry. Its business model focuses on a vertically integrated approach, managing the entire production cycle from growing cannabis plants to manufacturing and packaging derivative products like oils, edibles, and tinctures. This allows Greenrose to serve licensed dispensaries and registered medical cannabis patients in jurisdictions where such activities are legally permitted, positioning itself to meet the growing demand for specialized therapeutic cannabis applications.
How does The Greenrose Holding Company Inc. navigate regulatory challenges in the cannabis industry?
Operating in the cannabis industry means The Greenrose Holding Company Inc. faces a complex and constantly evolving regulatory landscape. The company must navigate a patchwork of state-specific laws governing cultivation, processing, distribution, and sales, while also contending with the federal illegality of cannabis in the United States. Compliance is paramount, requiring strict adherence to licensing requirements, product testing protocols, packaging standards, and marketing restrictions. Greenrose's strategy likely involves maintaining robust internal compliance teams, staying abreast of legislative changes, and adapting its operations to meet new regulations. This includes ensuring all products meet quality and safety standards mandated by health authorities in its operational markets, which is critical for maintaining its licenses and market access within the medical cannabis sector.
What are the implications of GNRS trading on the OTC market?
The Greenrose Holding Company Inc.'s listing on the 'OTC Other' tier of the OTC market carries significant implications for investors. This tier is characterized by minimal disclosure requirements, as evidenced by the company's 'Unknown' disclosure status, which severely limits the availability of financial and operational information. Consequently, investors face heightened risks due to a lack of transparency, potential for low liquidity, and wide bid-ask spreads, making it difficult to buy or sell shares at desired prices. The absence of robust regulatory oversight compared to major exchanges also increases the potential for volatility and makes thorough due diligence exceptionally challenging, requiring investors to exercise extreme caution and seek independent verification of any available company information.
What are the key growth opportunities for GNRS in the medical cannabis sector?
The Greenrose Holding Company Inc. has several key growth opportunities within the expanding medical cannabis sector. One significant avenue is the ongoing legalization of medical cannabis in new states, which could allow Greenrose to expand its operational footprint and patient reach. Another opportunity lies in product diversification, moving beyond traditional flower to a broader range of derivative products such as edibles, tinctures, and concentrates, catering to diverse patient preferences and therapeutic needs. Furthermore, enhancing vertical integration can improve cost efficiencies and quality control, while strategic partnerships or acquisitions could accelerate market penetration and scale operations. Lastly, investing in research and development to create specialized cannabis products for specific medical conditions could establish the company as a leader in niche therapeutic areas, driving long-term growth.
How does The Greenrose Holding Company Inc.'s financial profile reflect its market position?
The Greenrose Holding Company Inc.'s financial profile presents a complex picture. While the reported profit margin of 70.6% and gross margin of 59.1% indicate strong operational efficiency and potentially healthy unit economics in its cannabis manufacturing and distribution, the simultaneous reporting of a 2K market capitalization and a 0.00 P/E ratio suggests significant financial challenges or a very early stage of public market development. This combination implies either negligible or negative earnings, or that the market assigns a near-zero valuation despite high operational margins. The extremely high negative Beta of -170.34 further indicates an unusual and highly volatile relationship with the broader market. This profile suggests a company with potentially strong core business performance that is either highly distressed, undergoing significant restructuring, or facing severe market valuation discrepancies, reflecting a highly speculative market position.
What are the key factors to evaluate for GNRS?
The Greenrose Holding Company Inc. (GNRS) holds an AI score of 43/100 (low). P/E: 0.0x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does GNRS data refresh on this page?
GNRS prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven GNRS's recent stock price performance?
The Greenrose Holding Company Inc. (GNRS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: High profit margin of 70.6% and gross margin of 59.1% indicate strong operational efficiency. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial metrics (Market Cap, P/E, Beta, Margins) present contradictory signals; reported as provided without reconciliation.
- Limited information on CEO background and track record required generalization based on typical CEO roles in the industry.
- Growth opportunities and risks are inferred from the company's stated business and general industry context due to limited specific company data.
- Competitor information was not provided in the source data, hence 'Unknown' placeholder used.